Effectiveness of Postprandial Humalog in Toddlers With Diabetes
- 1 December 1997
- journal article
- clinical trial
- Published by American Academy of Pediatrics (AAP)
- Vol. 100 (6) , 968-972
- https://doi.org/10.1542/peds.100.6.968
Abstract
Objective. The purpose of this study was to determine whether postprandial administration of the new rapid-acting insulin analog Humalog could effectively reduce glucose excursions in children Design. Human Regular insulin given before a meal was compared with the same dose of Humalog after a meal of equal carbohydrate content in five toddlers with insulin-dependent (type 1) diabetes mellitus. In addition, the use of Humalog before a meal was compared with Humalog given after a meal of equal carbohydrate content in five other toddlers. The dose of long-acting insulin was not changed during the study period. Blood glucose levels were determined at fasting and at 1, 2, and 4 hours postprandially. Results. The 2-hour glucose excursions were significantly lower when postprandial Humalog administration was compared with preprandial Human Regular insulin administration. In contrast, glucose excursions were similar when Humalog was taken before or after the meal. Conclusion. These data show that it is efficacious to give Humalog insulin postprandially in toddlers with type 1 diabetes, allowing increased safety for the young child. The insulin dose can be both matched to the actual food intake and timed to give families increased flexibility and control at mealtime.Keywords
This publication has 6 references indexed in Scilit:
- Reduction of Postprandial Hyperglycemia and Frequency of Hypoglycemia in IDDM Patients on Insulin-Analog TreatmentDiabetes, 1997
- Intensive insulin therapy with insulin lispro in patients with type 1 diabetes reduces the frequency of hypoglycemic episodesExperimental and Clinical Endocrinology & Diabetes, 1996
- Pre-meal Insulin Analogue Insulin Lispro vs Humulin® R Insulin Treatment in Young Subjects with Type 1 DiabetesDiabetic Medicine, 1996
- Pharmacokinetics, pharmacodynamics and glucose counterregulation following subcutaneous injection of the monomeric insulin analogue [Lys(B28),Pro(B29)] in IDDMDiabetologia, 1994
- [Lys(B28), Pro(B29)]-Human Insulin: A Rapidly Absorbed Analogue of Human InsulinDiabetes, 1994
- Preparation of an Insulin with Improved Pharmacokinetics Relative to Human Insulin through Consideration of Structural Homology with Insulin-Like Growth Factor IHormone Research, 1994